WallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

Analyst price target for NVO

Based on 0 analysts offering 12 month price targets for Novo Nordisk A S.
Insufficient data to display

Should I buy or sell NVO stock?

Based on 1 analysts offering ratings for Novo Nordisk A S.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Deutsche Bank
Bottom 49%
49
Strong BuyInitiates Coverage OnN/AN/A2021-01-15

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
101.62%
Industry
9.04%
Market
59.49%
NVO's Return on Equity is forecast to be high in 3 years (101.62%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
42.04%
Industry
4.24%
Market
15.35%
NVO is forecast to generate higher Return on Assets (42.04%) than the US Biotechnology industry average (4.24%)
Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$3.09+5.58%
Avg 2 year Forecast
$3.36+14.71%
Avg 3 year Forecast
$3.75+27.86%
NVO's earnings are forecast to grow at a rate of 7.64% per year, which is not exceptional
Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$21.4B+6.32%
Avg 2 year Forecast
$23.4B+16.31%
Avg 3 year Forecast
$25.3B+25.6%
NVO's revenue is forecast to grow at a rate of 7.32% per year, which is not exceptional
Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
7.64%
Industry
38.19%
Market
18.23%
NVO's earnings are forecast to grow slower (7.64% per year) than the US Biotechnology industry average (38.19%)
Forecast
NVO's earnings are forecast to grow slower (7.64% per year) than the US market average (18.23%)
Forecast
NVO's earnings are forecast to grow faster (7.64% per year) than the risk-free savings rate (1.2%)
Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
7.32%
Industry
50.83%
Market
13.54%
NVO's revenues are forecast to grow slower (7.32% per year) than the US Biotechnology industry average (50.83%)
Forecast
NVO's revenues are forecast to grow slower (7.32% per year) than the US market average (13.54%)
Forecast

Novo Nordisk A S Stock Forecast FAQ

Is Novo Nordisk A S Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 1 Wall Street analysts covering (NYSE: NVO) stock is to Strong Buy NVO stock.

Out of 1 analysts, 1 (100%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 0 (0%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.

What is NVO's earnings growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of 7.64% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 38.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.23%.

Novo Nordisk A S's earnings in 2021 is $6,913,548,387.On average, 4 Wall Street analysts forecast NVO's earnings for 2021 to be $7,267,375,000, with the lowest NVO earnings forecast at $7,144,000,000, and the highest NVO earnings forecast at $7,473,000,000. On average, 4 Wall Street analysts forecast NVO's earnings for 2022 to be $7,896,000,000, with the lowest NVO earnings forecast at $7,778,500,000, and the highest NVO earnings forecast at $8,131,000,000.

In 2023, NVO is forecast to generate $8,800,750,000 in earnings, with the lowest earnings forecast at $8,742,000,000 and the highest earnings forecast at $8,859,500,000.

What is NVO's revenue growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 7.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.

Novo Nordisk A S's revenue in 2021 is $20,463,709,677.On average, 3 Wall Street analysts forecast NVO's revenue for 2021 to be $50,318,881,500,000, with the lowest NVO revenue forecast at $49,781,154,500,000, and the highest NVO revenue forecast at $50,695,328,000,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $55,044,285,000,000, with the lowest NVO revenue forecast at $54,029,978,000,000, and the highest NVO revenue forecast at $56,045,949,000,000.

In 2023, NVO is forecast to generate $59,444,244,050,000 in revenue, with the lowest revenue forecast at $58,863,552,000,000 and the highest revenue forecast at $60,550,264,500,000.

What is NVO's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVO) forecast ROA is 42.04%, which is higher than the forecast US Biotechnology industry average of 4.24%.

What is NVO's Price Target?

According to 0 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is N/A, with the highest NVO stock price forecast at N/A and the lowest NVO stock price forecast at N/A.

On average, Wall Street analysts predict that Novo Nordisk A S's share price could stay at N/A by Jan 15, 2022. The average Novo Nordisk A S stock price prediction forecasts a potential downside of N/A from the current NVO share price of $92.60.

What is NVO's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $2.98. On average, analysts forecast that NVO's EPS will be $3.09 for 2021, with the lowest EPS forecast at $3.04, and the highest EPS forecast at $3.18. On average, analysts forecast that NVO's EPS will be $3.36 for 2022, with the lowest EPS forecast at $3.31, and the highest EPS forecast at $3.46. In 2023, NVO's EPS is forecast to hit $3.75 (min: $3.72, max: $3.77).

What is NVO's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVO) forecast ROE is 101.62%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.